Literature DB >> 8948444

Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties.

S J Milner1, G L Francis, J C Wallace, B A Magee, F J Ballard.   

Abstract

The oxidative folding of human insulin-like growth factor (IGF)-I yields two major disulphide folding isomers. In the present study, B-domain analogues of IGF-I were used to investigate the effect of mutations on the folding reaction and to investigate the functional implications of misfolding. The analogues used were substitutions of the native Glu3 by Gly or Arg, or the native Glu9 by Lys. IGF-I and these analogues were also prepared attached to a hydrophobic 13-amino-acid N-terminal extension, Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn, referred to as 'Long-IGF-I' analogues. Each IGF was fully reduced and refolded to yield native and misfolded isomers, which were subsequently purified for biological characterization. Analysis of the folding reaction at equilibrium revealed a distribution of folding isomers characteristic for each peptide. The yield of the native disulphide folding isomer was increased for the Glu3 substitutions, but not for the Glu9 substitution. The main alternative folding isomer was present in the IGF-I analogues in reduced proportions. Except for [Gly3]IGF-I the N-terminal extension increased the yield of the native isomer which was maximal for the analogue Long-[Arg3]IGF-I. A folding intermediate for the latter analogue was isolated and partially characterized. The biological assays showed that all the main alternative isomers bound poorly to IGF-binding proteins (IGFBPs) secreted by L6 myoblasts. Moreover, these isomers bound to the type 1 IGF receptor with 0.5-25% the affinity of the native isomer. In a rat L6 myoblast protein-synthesis assay, the observed biological activity of the native and main alternative isomers was explained by their modified IGFBP- and receptor-binding properties. We propose that the N-terminal extension imparts a steric constraint at a crucial point in folding, thus allowing native disulphide bonds to form efficiently.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8948444      PMCID: PMC1136804          DOI: 10.1042/bj3080865

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1.

Authors:  M Ross; G L Francis; L Szabo; J C Wallace; F J Ballard
Journal:  Biochem J       Date:  1989-02-15       Impact factor: 3.857

2.  Principles that govern the folding of protein chains.

Authors:  C B Anfinsen
Journal:  Science       Date:  1973-07-20       Impact factor: 47.728

3.  Purification and partial sequence analysis of insulin-like growth factor-1 from bovine colostrum.

Authors:  G L Francis; L C Read; F J Ballard; C J Bagley; F M Upton; P M Gravestock; J C Wallace
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

4.  A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide.

Authors:  C J Bagley; B L May; L Szabo; P J McNamara; M Ross; G L Francis; F J Ballard; J C Wallace
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

5.  Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors.

Authors:  M A Cascieri; G G Chicchi; J Applebaum; B G Green; N S Hayes; M L Bayne
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

6.  Direct identification of disulfide bond linkages in human insulin-like growth factor I (IGF-I) by chemical synthesis.

Authors:  M Iwai; M Kobayashi; K Tamura; Y Ishii; H Yamada; M Niwa
Journal:  J Biochem       Date:  1989-12       Impact factor: 3.387

7.  Insulin-like growth factor: a model for tertiary structure accounting for immunoreactivity and receptor binding.

Authors:  T L Blundell; S Bedarkar; E Rinderknecht; R E Humbel
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

8.  The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding.

Authors:  L Szabo; D G Mottershead; F J Ballard; J C Wallace
Journal:  Biochem Biophys Res Commun       Date:  1988-02-29       Impact factor: 3.575

9.  Folding of insulin-like growth factor I is thermodynamically controlled by insulin-like growth factor binding protein.

Authors:  S Hober; A Hansson; M Uhlén; B Nilsson
Journal:  Biochemistry       Date:  1994-06-07       Impact factor: 3.162

10.  Mitogen-potentiating action and binding characteristics of insulin and insulin-like growth factors in Chinese hamster fibroblasts.

Authors:  E Van Obberghen-Schilling; J Pouysségur
Journal:  Exp Cell Res       Date:  1983-09       Impact factor: 3.905

View more
  2 in total

1.  Engineering insulin-like growth factor-1 for local delivery.

Authors:  Tomotake Tokunou; Rachel Miller; Parth Patwari; Michael E Davis; Vincent F M Segers; Alan J Grodzinsky; Richard T Lee
Journal:  FASEB J       Date:  2008-02-19       Impact factor: 5.191

2.  Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II.

Authors:  Clair L Alvino; Shee Chee Ong; Kerrie A McNeil; Carlie Delaine; Grant W Booker; John C Wallace; Briony E Forbes
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.